FDA Approves Neurotech Company for Testing Brain Chip in Humans

FDA Approves
Neurotech Company, for Testing Brain Chip, in Humans.
FDA Approves
Neurotech Company, for Testing Brain Chip, in Humans.
Activist Post reports that brain-computer interface, or BCI, represents the latest frontier of artificial intelligence and biology.
While this technology is still early in development,
a growing number of companies are already
looking at its commercial applications.
On July 28, one of those companies, New York startup Synchron, received FDA approval to test its brain device in human patients.
Stentrode, Synchron’s implantable device, is small enough to be implanted via a blood vessel at the base of the neck.
The device is then maneuvered
toward a vessel in the brain.
Stentrode works
by communicating
through a tiny wire
with a second implant
in the chest.
A transmitter then sends signals to an external computer near the patient.
We have worked together to pave
a pathway forward, towards
the first commercial approval
for a permanently implanted BCI
for the treatment of paralysis, Thomas Oxley, Synchron CEO, via Activist Post.
We have worked together to pave
a pathway forward, towards
the first commercial approval
for a permanently implanted BCI
for the treatment of paralysis, Thomas Oxley, Synchron CEO, via Activist Post.
The company plans to enroll six patients
in its U.S. trial later this year.
According to Oxley, the U.S. study will take
a closer look at safety issues, including
physical risks and cybersecurity.
Activitst Post reports an FDA-approved product could be on the market in as soon as 3 to 5 years